Reprint
Anticancer Drugs 2021
Edited by
May 2022
594 pages
- ISBN978-3-0365-4348-2 (Hardback)
- ISBN978-3-0365-4347-5 (PDF)
This book is a reprint of the Special Issue Anticancer Drugs 2021 that was published in
Biology & Life Sciences
Chemistry & Materials Science
Medicine & Pharmacology
Summary
The Special Issue "Anticancer Drugs 2021" of Pharmaceuticals is focused on recent significant advances in the design, synthesis, molecular mechanism of action and therapeutic applications of anticancer drugs. This collection of preclinical research papers and reviews includes designed chemotherapeutic agents, targeted therapies and biological agents. The rationalization for the biological activity of these drugs is presented, which helps to guide the design of more effective agents. Structure–activity relationships, together with the biological context in which targets are selected for oncology drug development, are also considered.
Format
- Hardback
License
© 2022 by the authors; CC BY-NC-ND license
Keywords
thymidylate synthase; cytotoxicity; 1,2,3-triazole; 1,3,4-oxadiazole; 5-fluoruracil; pemetrexed; docking; 3,4′-bis-guanidino; 3-amino-4′-guanidino; diphenyl ether; phenyl pyridyl ether; intramolecular hydrogen bond; cancer cell viability; HL-60; BRAF; apoptosis; thieno[2,3-d][1,2,3]triazine; acetamide; H1299; HER2; EGFR; Bcl-2 inhibitors; Indole-based analogues; benzimidazole; MTT cytotoxic assay; cell cycle analysis; DNA fragmentation; ELISA; docking; solid/lipid nanoparticles; phenstatin; letrozole; tubulin polymerisation inhibitor; aromatase inhibitor; breast cancer; hybrid molecule; dual-targeting molecule; apoptosis; designed multiple ligand; NaMSA; cyclophosphamide; histopathology; testis; urinary bladder; anticancer agents; cytotoxicity; enantioselective synthesis; gastric adenocarcinoma; tryptophanol; concentration-guided dosing; model informed dosing; physiologically based pharmacokinetics; sorafenib; tyrosil-DNA-phosphodiesterase 1; adamantane; resin acid; TDP1; cytotoxic agents; apoptosis induction; HT-29 cells; MDA-MB-231 cells; mechanism prediction; STAT inhibitors; miR-21; hydrazide derivatives; nitrogen scaffolds; mitoxantrone; cardiotoxicity; inflammation; oxidative stress; age; cumulative dose; Trk; NTRK; tissue-agnostic; larotrectinib; entrectinib; Trk fusion; protein kinase inhibitors; USFDA; cancer; inflammation; patent review; generic product; HER2; EGFR; doxazosin; docking; MD simulations; cancer; combretastatin A-4; cytotoxic activity; hybrid compounds; indazole; mucin; MUC1; MUC16; immunotherapy; cancer vaccine; CAR (chimeric antigen receptor); ADC (antibody-drug conjugate); thiourea; cytotoxic activity; apoptosis; interleukin-6; trypan blue assay; chalcones; exportin-1; covalent binding; CovDock; anticancer activity; xanthone; cancer; in vitro; in vivo; isolation; synthesis; heterocyclic compound; benzenesulfonamides; imidazoles; alkylated; anticancer activity; colony formation; tumor spheroids; cancer; hybrid compounds; EGFR; HDAC inhibitors; chalcone; dual inhibitors; cyclophosphamide; carvedilol; urinary bladder; kidney; oxidative stress; toxicity; 7-deaza-4′-thioadenosine derivatives; multi-kinase inhibitor; anticancer; nucleoside; Imiquimod; drug efflux; multidrug resistance; immunotherapy; Toll-Like Receptor; n/a